SynBiotic (SCALE: SBX)

Last close As at 20/12/2024

EUR4.20

−0.65 (−13.40%)

Market capitalisation

EUR20m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer | Outlook

SynBiotic — Platform primed for growth

Consumer | Outlook

SynBiotic — Building the platform

Consumer | Update

SynBiotic — Management update – on track

Consumer | Update

SynBiotic — Further acquisitions

Sector

Consumer

Equity Analyst

Russell Pointon

Russell Pointon

Director of Content, Consumer and Media

Key Management

  • Daniel Kruse

    CEO

Research

Update

Consumer

SynBiotic — Further acquisitions

QuickView

Consumer

SynBiotic — Building a cannabis platform

Initiation

Consumer

SynBiotic — Working together

Thematics

thematic

Consumer

ConsumerWatch – Don’t look down

thematic

Consumer

ConsumerWatch – The times they are a-changin’

thematic

Consumer

ConsumerWatch – Give me a reason to love you

thematic

Consumer

ConsumerWatch – At least someone loves me

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free